Abstract 284P
Background
Follicular Lymphoma (FL) is known to be a disease of the elderly and younger patients are postulated to have distinct tumor biology and treatment outcomes. Various lymphoma groups across the world have studied this to understand if young adults (YA) need a different treatment approach. Our study fills the void in paucity of data from an Asian country on YA versus older population of Follicular Lymphoma.
Methods
The records of patients presented at our center between 2012 and 2018 were retrospectively reviewed. They were stratified by age into ≤40 (YA) and > 40 years and their demographics, clinicopathological features and outcomes were analyzed.
Results
A total of 167 patients of follicular lymphoma were identified with 24 (14.3%) patients belonging to YA group. A final analysis of 154 patients is presented after excluding patients with upfront Grade 3b disease. Median age in YA and older patients was 37 and 55 years respectively. YA group had a higher incidence of extranodal involvement, bone marrow involvement, and advanced disease at presentation, whereas high LDH and low hemoglobin levels were more common in older patients. As per FLIPI risk scoring, 43% of our patients in both groups had high-risk disease. All YA received treatment upfront, while 7.7% of older population underwent observation. Most commonly used chemotherapy regimen was CVP and 46% of our patients received Rituximab. The ORR was significantly more in YA population (91.3% vs 83.2%) At a median follow-up of 3.5 and 3.2 years (YA and >40 years respectively), YA had a better median PFS (3.5 yrs) and OS (5.9 yrs) compared to those older than 40 (PFS 3.1 yrs, OS 5.2 yrs). On multivariate analysis, normal LDH, lower FLIPI score and use of Rituximab were associated with a significantly longer PFS in older patients, however, it showed a trend towards improved PFS in young adult population that did not reach statistical significance. No parameter showed a significant association with OS.
Conclusions
YA more frequently present with advanced stage requiring upfront treatment, however they exhibit higher ORR and better PFS and OS compared to older counterparts. The survival rates seen are comparable to another Indian study but lower than the Western data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract